Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer.

ABSTRACT:

Background

Inflammatory breast cancer (IBC) is a highly angiogenic disease; thus, antiangiogenic therapy should result in a clinical response. However, clinical trials have demonstrated only modest responses, and the reasons for these outcomes remain unknown. Therefore, the purpose of this retrospective study was to determine the prognostic value of protein levels of vascular endothelial growth factor (VEGF-A), one of the main targets of antiangiogenic therapy, and its receptors (VEGF-R1 and -R2) in IBC tumor specimens.

Patients and methods

Specimens from IBC and normal breast tissues were obtained from Algerian patients. Tumor epithelial and stromal staining of VEGF-A, VEGF-R1, and VEGF-R2 was evaluated by immunohistochemical analysis in tumors and normal breast tissues; th

SUBMITTER: Arias-Pulido H 

PROVIDER: S-EPMC3474178 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature